ÂÜÀòÂÒÂ×

Dr Michael Owen, aged 68, has worked in biomedical research, and in the pharmaceutical and biotechnology industries for nearly 40 years. He is the co-founder and first CSO of Kymab Ltd, a biopharmaceutical company based in Cambridge, UK, prior to which he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Dr Owen currently serves on the boards of several public and private biotechnology companies in the UK, Europe and the USA, including ReNeuron plc, GammaDelta Therapeutics and Zealand Pharma A/S. He is also the Chairman of Ossianix Inc. In addition, Dr Owen is Chairman of ReNeuron’s scientific advisory board, an advisor to Abingworth LLP and was until recently an advisor to the CRT Pioneer Fund. Dr Owen received a MA from Oxford University and a PhD from Cambridge University, and is an elected member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.